Invention Grant
- Patent Title: Vitronectin receptor antagonist pharmaceuticals
- Patent Title (中): Vitronectin受体拮抗剂药物
-
Application No.: US10348268Application Date: 2003-01-21
-
Publication No.: US07090828B2Publication Date: 2006-08-15
- Inventor: Edward H. Cheesman , John A. Barrett , Alan P. Carpenter, Jr. , Milind Rajopadhye , Michael Sworin
- Applicant: Edward H. Cheesman , John A. Barrett , Alan P. Carpenter, Jr. , Milind Rajopadhye , Michael Sworin
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Pharma Company
- Current Assignee: Bristol-Myers Squibb Pharma Company
- Current Assignee Address: US NJ Princeton
- Agency: Woodcock Washburn LLP
- Main IPC: A61K5/00
- IPC: A61K5/00 ; A61M36/14

Abstract:
The present invention describes novel compounds of the formula: (Q)d-Ln-Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.
Public/Granted literature
- US20040014964A1 Vitronectin receptor antagonist pharmaceuticals Public/Granted day:2004-01-22
Information query